Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06545734
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion A Randomized Controlled Pilot Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to determine if direct ischemic post-conditioning IPostC can alleviate ischemic-reperfusion injury IR in patients who have undergone endovascular thrombectomy EVT Additionally the study aims to explore the underlying mechanisms of direct IPostC
The primary questions this trial seeks to answer are
1 Is direct IPostC effective for acute stroke patients with large vessel occlusion
2 What are the underlying mechanisms of direct IPostC
Participants will be randomly assigned to one of two groups an EVT alone group or an EVT plus direct IPostC group Direct IPostC will be administered immediately after EVT through four cycles of mechanical interruptions of reperfusion We will evaluate outcomes based on final infarct volume infarct volume growth clinical parameters and IR-related imaging and laboratory biomarkers Additionally an exploratory multi-omics analysis will be conducted to uncover the detailed mechanisms of direct IPostC
The primary questions this trial seeks to answer are
1 Is direct IPostC effective for acute stroke patients with large vessel occlusion
2 What are the underlying mechanisms of direct IPostC
Participants will be randomly assigned to one of two groups an EVT alone group or an EVT plus direct IPostC group Direct IPostC will be administered immediately after EVT through four cycles of mechanical interruptions of reperfusion We will evaluate outcomes based on final infarct volume infarct volume growth clinical parameters and IR-related imaging and laboratory biomarkers Additionally an exploratory multi-omics analysis will be conducted to uncover the detailed mechanisms of direct IPostC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None